Status:
RECRUITING
Pathogenic Metagenomic Next-generation Sequencing to Optimize the Diagnosis of Decompensated Cirrhosis Infection
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Cirrhosis, Liver
Eligibility:
All Genders
18-80 years
Brief Summary
The goal of this observational study is to learn about clinical application of pathogenic metagenomic next-generation sequencing to optimize the diagnosis of infection in decompensated cirrhotic patie...
Detailed Description
Metagenomic next-generation sequencing (mNGS) is emerging as an important culture-independent technique that can detect nearly all known pathogens simultaneously from a clinical sample.Sequencing of m...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old.
- Diagnosis of cirrhosis, previously known or not, of any etiology, histologically proven or not.
- Acute decompensation: ascites, digestive hemorrhage or hepatic encephalopathy.
Exclusion
- Age \> 80 years old.
- Malignancy of liver or other organs (including leukemia).
- Receiving immunosuppressive agents for non-hepatic diseases.
- HIV infection.
Key Trial Info
Start Date :
February 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2025
Estimated Enrollment :
850 Patients enrolled
Trial Details
Trial ID
NCT06039696
Start Date
February 10 2021
End Date
March 30 2025
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital
Guangzhou, Guangdong, China